Zai Lab discloses $249.9 million private securities offering in SEC Form D
The filing shows all shares already sold to 25 investors, with Leerink Partners serving as placement agent.
Zai Lab Ltd, a Cayman Islands exempted company with its principal office in Cambridge, Massachusetts, filed a Form D with the Securities and Exchange Commission on November 9, 2026, disclosing a securities offering under Rule 506(b) of Regulation D. The filing lists a date of first sale of October 27, 2026.1
The total offering amount and total amount sold were both listed as $249,933,600, with $0 remaining to be sold.1 The filing states that 25 investors have already invested in the offering.1 The securities offered were equity.1
The issuer indicated the offering was not intended to last more than one year.1 The filing also states this offering was not made in connection with a business combination transaction such as a merger, acquisition or exchange offer.1 The minimum investment accepted from any outside investor was listed as $0.1
Leerink Partners LLC, based at 53 State Street in Boston, is named as a recipient of sales compensation in connection with the offering.1 The filing reports sales commissions of $7,498,008 and finders' fees of $0.1 The amount of proceeds proposed for use in payments to executive officers, directors or promoters named in the filing was listed as $0.1
Zai Lab identified its industry group as biotechnology within the health care sector.1 The Form D was signed on behalf of Zai Lab Ltd by Chief Financial Officer Yajing Chen, Ph.D., dated November 9, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.